Related Experiment Videos
Papaverine inhibits human platelet aggregation induced by ADP
M I Serro-Azul1, S P Bydlowski, D A Chamone
1Laboratório de Pesquisa, Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Brasil.
Summary
Papaverine effectively inhibits human platelet aggregation in whole blood, particularly when interacting with red blood cells. This effect was observed both in vitro and after oral administration in healthy volunteers.
Area of Science:
- Pharmacology
- Hematology
- Cardiovascular Research
Background:
- Platelet aggregation is a key factor in thrombosis.
- Papaverine is an alkaloid with vasodilator properties.
- Understanding papaverine's antiplatelet effects is crucial for cardiovascular health.
Purpose of the Study:
- To evaluate the in vitro and ex vivo effects of papaverine on human platelet aggregation.
- To investigate the role of red blood cells in papaverine's antiplatelet activity.
- To assess the impact of oral papaverine administration on platelet function.
Main Methods:
- In vitro and ex vivo aggregometry (photometric and impedance) in platelet-rich plasma and whole blood.
- Evaluation of adenosine diphosphate (ADP)-induced platelet aggregation.
- Pharmacokinetic analysis following oral papaverine administration in healthy volunteers.
- In vitro studies using rat whole blood.
Main Results:
- Papaverine significantly inhibited ADP-induced platelet aggregation in whole blood, an effect potentiated by erythrocytes.
- Oral papaverine administration reduced platelet aggregation in whole blood.
- A negative correlation was found between plasma papaverine levels and platelet aggregation.
- Papaverine did not affect platelet aggregation in rat whole blood.
Conclusions:
- Papaverine inhibits human platelet aggregation in whole blood.
- Red blood cells play a significant role in mediating papaverine's antiplatelet effects.
- Papaverine demonstrates potential as an antiplatelet agent, particularly in whole blood assays.